Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- 4 Eligibility Criteria Presented for Conditional Early Approval System
June 2, 2017
- 3rd Sakigake Invitation for Drugs Slated for This Autumn: MHLW
June 2, 2017
- Honebuto Policy to Incorporate Timeline for Drug Pricing Overhaul
June 2, 2017
- MHLW Proposes Thresholds for 5-Scale Cost-Effectiveness Ratings: Chuikyo
June 1, 2017
- Chuikyo Members Oppose Reference Pricing System for LLPs
June 1, 2017
- Payer Reps Push Earlier Application of “Z2” Price Cut for LLPs with Low Gx Rates: Chuikyo
June 1, 2017
- MHLW Advisory Panel Gives Nod to Eli Lilly’s JAK Inhibitor Baricitinib
May 31, 2017
- PhRMA Calls for Expedited Discussions on Inclusion of Vaccines in Public Vaccination Programs
May 31, 2017
- MHLW to Take Strict Action on Xarelto Side Effect Case: Minister
May 31, 2017
- MHLW Orders Label Revisions for Pneumovax NP, 3 Other Products
May 31, 2017
- Lyrica OD Tablets, Other New Dosage Forms to Join NHI Price List on May 31
May 30, 2017
- MHLW Orders Bayer Blanket Probe on Side Effect Reporting
May 30, 2017
- Nusinersen, Tenelia-Canaglu Combo Up for MHLW Panel Review on June 9
May 29, 2017
- Off-Year Revision of NHI Prices “Should Be as Restricted as Possible”: LDP Lawmakers
May 29, 2017
- MOF Panel Calls for Abolishing Price Maintenance Premium, Further Belt-Tightening
May 26, 2017
- MEXT to Probe Company Payments to National Univ. Hospitals: Parliamentary Vice Minister
May 25, 2017
- Suga Tacitly Warns against Watering Down “Annual” Price Revision Plan: CEFP
May 24, 2017
- CEFP Private Members Push Smaller Scope for Price Maintenance Premium, Different Rule for “Me-Too” Meds
May 24, 2017
- Health Minister Pitches Revision to Corporate Eligibility Criteria for Price Maintenance Premium: CEFP
May 24, 2017
- Time Has Arrived to Discuss Formularies at Medical Institutions: MHLW Official
May 23, 2017
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…